Start 30 days free, no card. Full Pro access for a month, then decide. Start free

Back to analysts list

Analyst

Harris Fein

Wolfe Research · covers Basic Materials

Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q2 (7 quarters; questions recorded in 4).

Limited coverage. Only 6 questions of coverage. Treat these numbers as directional — sample too small for reliable averages.
Questions
6on tracked calls
Challenge rate
0%none of 6 questionsLimited sample
Companies
3questioned at least once
Reporting periods
4with questions

These figures cover the whole profile: every tracked question, all reporting periods.

How to read these numbers

Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.

Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.

No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.

Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.

Small samples. Profiles with fewer than 10 questions are marked Limited sample.

Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.

Questions asked

Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.

Showing 6 of 6 questions from 3 companies

IFFInternational Flavors & Fragrances3 questions · 3 reporting periods · 0 of 3 challenging
IFF company page →

Calendar 2026 Q1

On the Taste margins, they came in a fair bit better than we were expecting on, say, not a huge amount of organic growth. So can we just zoom in on what's happening there?

Show response

DeVeau attributed Taste margin to three factors: good volume growth and leverage, favorable net price-to-input cost, and disciplined productivity. Cautioned 18% CCN EBITDA growth is unusually high and will normalize due to timing of inventory absorption.

Calendar 2025 Q3

there's been some solid year-on-year margin comps in Food Ingredients. Just wondering if you could maybe talk about the line of sight to bridge that margin to the mid-teens next year

Show response

DeVeau traced Food Ingredients margin from 9% to 12% to ~14% adjusted for portfolio, with clear line of sight to 15%. Growth return plus ongoing plant and raw material optimization are the levers. Erik added TAURA fruit inclusions capacity expansion as example of investing in high-margin growth areas.

Calendar 2024 Q4

what does that price discovery mean to you in terms of maybe whether you could prune a little bit more from your portfolio

M&ACapital AllocationTranscript · FY2024 Q4 →
Show response

Erik acknowledged potential further food ingredients pruning and described bolt-on strategy focused on HNB technologies and taste geographic footprint, with emphasis on returns.

ALBAlbemarle Corporation2 questions · 1 reporting period · 0 of 2 challenging
ALB company page →

Calendar 2025 Q3

Just curious to hear what the latest you're hearing is

Regulation PolicyCapex InvestmentTranscript · FY2025 Q3 →
Show response

Masters emphasized the need for multiple tools, tax incentives, trade policy, direct investment, public-private partnerships, noting no single solution will suffice.

How much of that was just you being opportunistic on spot sales because of price volatility?

Show response

Masters acknowledged the inventory drawdown provided extra growth this year that won't repeat in 2026, but noted the underlying market demand remains strong.

DDDuPont1 question · 1 reporting period · 0 of 1 challenging
DD company page →

Calendar 2026 Q2

can you just give us an update on the M&A pipeline? It seems like you have capacity for both buybacks and midsize M&A.

M&ACapital AllocationTranscript · FY2026 Q2 →
Show response

Koch cited >$1B M&A capacity plus a $250M buyback, targeting mid-teens gross valuations in CDMO/packaging.

Challenge rate by company

Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.

CompanyQuestionsChallenge rate
IFF International Flavors & Fragrances30%none of 3 questions
ALB Albemarle Corporation2—Rate withheld: fewer than 3 questions
DD DuPont1—Rate withheld: fewer than 3 questions
  • IFF
    International Flavors & Fragrances · 3 questions
    0%none of 3 questions
  • ALB
    Albemarle Corporation · 2 questions
    —rate withheld: under 3 questions
  • DD
    DuPont · 1 question
    —rate withheld: under 3 questions

Activity by reporting period

Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.

Questions by calendar reporting period
Calendar periodQuestionsChallenge rateCompanies
2024 Q410%none of 1 question1
2025 Q1No questions recorded——
2025 Q2No questions recorded——
2025 Q330%none of 3 questions2
2025 Q4No questions recorded——
2026 Q110%none of 1 question1
2026 Q210%none of 1 question1
  1. 2024 Q41 question · challenge rate 0% (none of 1 question) · 1 company
  2. 2025 Q1No questions recorded
  3. 2025 Q2No questions recorded
  4. 2025 Q33 questions · challenge rate 0% (none of 3 questions) · 2 companies
  5. 2025 Q4No questions recorded
  6. 2026 Q11 question · challenge rate 0% (none of 1 question) · 1 company
  7. 2026 Q21 question · challenge rate 0% (none of 1 question) · 1 company

Topics

Topics tagged on this analyst’s questions.

  • M&A3
  • Capital Allocation2
  • Margin2
  • Pricing1
  • Regulation Policy1
  • Capex Investment1
  • Demand1
  • Inventory1